Central Venous Catheter vs Midline in Difficulty Access Patient - A Randomized Controlled Clinical Pilot Trial - Pilot-ACCESS-D
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Percentage of participants who complete all study procedures accordingly. (Feasibility)
研究概览
简要总结
Intravenous access is a necessity for nearly all inpatient medical care. Approximately half of hospitalized patients require a peripheral venous catheter (PVC), either to enable administration of medications intravenously or to repeatedly draw blood samples (1). Establishing a venous access sometimes requires repeated attempts, resulting in multiple needle sticks and prolonged discomfort for patients. In addition, this may lead to a diminished healthcare experience and create a stressful situation for both patients and healthcare personnel (2, 3). Delays in establishing intravenous access can result in setbacks in sample collection and drug administration (4, 5).
Difficult Intravenous Access (DIVA) is a situation that arises "when two or more clinicians fail two or more times to establish a peripheral access using conventional techniques, when a patient lacks visible or palpable veins or the patient has a stated or documented history of DIVA" (6). The prevalence of DIVA varies from 6% to 88% in different studies, primarily due to variations in definition of DIVA. Known risk factors are diabetes, intravenous drug abuse, sex (higher risk for women), chronic illness, obesity, malnutrition, absence of visible or palpable veins (7, 8). Although it is possible to establish a short, standard-length PVC through the help of ultrasound-guidance, this approach has limited scientific support (4, 9-11). In addition, ultrasound-guided PVCs are not health economically justifiable (12).
There are a handful of alternatives in terms of vascular access devices (VAD) for DIVA patients: Standard short PVC, Midline catheter, Central Venous Catheter (CVC) and Peripherally Inserted Central Catheter (PICC). A Midline is a long (8-12 cm), peripherally inserted venous catheter that is most commonly inserted into the upper arm via the basilic, cephalic or brachial veins, with its tip terminating below the level of the axilla (13). A Central Venous Catheter (CVC) is inserted through one of several veins (subclavian, jugular, or femoral) and terminates in a central vein, typically the superior vena cava, right atrium, or the iliac/inferior vena cava, depending on the insertion site. A PICC is an extended venous catheter inserted peripherally, similar to the Midline, inserted through the veins of the upper arm. However, the PICC terminates centrally, in the superior vena cava. There is some existing evidence supporting that Midline catheters could be safer compared to PICCs in short term (14-16). Today, CVCs are standard of care in many centers, but retrospective data indicate that Midlines could be a feasible option in DIVA patients (17). Furthermore, CVC insertion involves certain risks, such as arterial puncture, hematoma or pneumothorax (18). For DIVA patients in need of venous access for 5 days or more, Midlines are preferred as per the Michigan Appropriateness Guide for Intravenous Catheters (MAGIC) guidelines (13). However, there are no randomized controlled clinical trials comparing Midlines to CVCs in DIVA patients.
Primary aim of study The aim of the study is to test the feasibility of the study protocol before a future large-scale RCT.
详细描述
Methods CONSORT Methods This pilot trial is a randomized, controlled, two-armed study with a sample size of 30 patients. A sample size of 30 is chosen as a convenience sample. The study will be conducted in Ryhov county hospital, in southern Sweden. Hospitalized patients across adult somatic wards with difficult intravenous access, are screened for potential trial recruitment. Patients are identified when staff from the ward contact the vascular access nurse. All inclusion and exclusion criteria are presented in Table 1. Patients identified, screened, and deemed eligible will be approached with study information. The trial is planned in accordance with the CONSORT guidelines for pilot trials (19).
Setting The patient flowchart, depicted in Figure 1, outlines the vascular access procedures at Ryhov County Hospital. This process involves collaboration between a ward nurse and an anesthesia (vascular access) nurse. In case the ward nurse encounters difficulties in establishing venous access, patients are referred to the anesthesia nurse accordingly.
The insertion of catheters occurs in a dedicated post-op area. Clinicians in this setting have the option to choose between establishing a Midline catheter guided by ultrasound or opting for a Central Venous Catheter (CVC), also guided by ultrasound (USG).
Recruitment, Randomization and Blinding Patients are assessed by the vascular access clinician in the Post-op ward. The recruitment process takes place in collaboration with anesthesiologists from the Acute Care and Trauma unit. Written consent and information are obtained by the physician. Subsequently, patients are randomized by the trial clinician using StudyRandomizer (https://www.studyrandomizer.com). Due to the visible nature of the intervention, blinding is not feasible. Trial participants are randomized in a 1:1 ratio using a block size of 6.
Patient identification, screening, and recruitment are outlined in Figure 1. After obtaining written consent, randomization, allocation and insertion of the VAD, patients return to their respective wards.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •• Age 18 and over
- •DIVA criterium fulfilled;
- •2 attempts of venous access by 2 clinicians OR
- •No visible nor palpable veins OR
- •History of difficult venous access
- •4 - 29 days of catheter dwell time anticipated as assessed by referring clinician.
排除标准
- •Unable to speak Scandinavian
- •Cognitive Impairment
- •Is to receive hyperosmolar solutions (600 milliosmoles/L or above).
- •Is to receive chemotherapy
结局指标
主要结局
Percentage of participants who complete all study procedures accordingly. (Feasibility)
时间窗: From screening to 29 days after enrollment
Feasibility is defined as the percentage of participants who complete all study procedures as per protocol. Assesed using screening logs, case report forms, follow-up logs and collected data base.
Percentage of screened patients eligible to participate. (Eligibility)
时间窗: At screening.
Eligibility is defined as the percentage of screened patients who meet the inclusion criteria and are eligible to participate in the study. Assessed by screening logs and eligibility criteria checklists.
Percentage of eligible patients who consent to participate. (Recruitment)
时间窗: At recruitment to 29 days after recruitment.
Recruitment is defined as the percentage of eligible patients who provide informed consent to participate in the trial. Assessed by consent logs.
Percentage of patients retained in the study. (Retention and attrition)
时间窗: From randomization to 29 days after enrollment
Retention and attrition is defined as the percentage of patients retained in the study, excluding those lost to follow-up or who withdrew consent. Assessed by follow-up forms.
Percentage of patients adhering to randomized intervention. (Adherence)
时间窗: From randomization to 29 days after enrollment
Adherence is defined as the percentage of enrolled patients who receive their randomized intervention as per protocol. Assesed by case report forms.
Percentage of patients with incomplete data. (Missing data)
时间窗: From randomization to 29 days after enrollment
Missing data is defined as having less than 10% of enrolled patients' data incomplete. Assesed through case report forms and collected database.
Percentage of patients requiring multiple venipunctures. (Venipuncture attempts)
时间窗: At insertion.
Venipuncture attempts are defined as the percentage of enrolled patients requiring 2 or more venipunctures per insertion. Assesed through case report forms.
次要结局
- Insertion time, minutes(At insertion)
- Dwell time, days(From randomization to 29 days after enrollment)
- Number of patients with complications.(From randomization to 29 days after enrollment)
